APLS
Apellis Pharmaceuticals, Inc.Company with tickers: APLS
CIK
1492422
CUSIP
03753U106
Shares Outstanding
128,021,277
13F Activity (30d)
288 filings
283 filers
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | $268,295,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $241,828,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Research & Development | $76,958,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Operating Income | $26,467,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Net Income | $18,656,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| EPS (Basic) | $0.15 | USD/shares | 2026-03-31 | 10-Q | 2026-05-07 |
| EPS (Diluted) | $0.15 | USD/shares | 2026-03-31 | 10-Q | 2026-05-07 |